Clinical Trial Update: Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness [Phase 1]

View source ↗

Summary

Phase 1 safety study of PT-523 in cancer patients with solid tumors has been terminated; the trial collected safety data and a preliminary assessment of effecti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• PT-523

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Neoplasms | Phase 1 | Status: TERMINATED